Cardiol Therapeutics (TSE:CRDL) has released an update.
Cardiol Therapeutics has successfully enrolled 100 patients in its Phase II ARCHER trial, testing CardiolRx™ in treating acute myocarditis, a serious inflammatory heart condition. The trial’s results, expected next year, could provide significant insights into the drug’s impact on heart recovery, with no current FDA-approved treatments for this condition. The company sees this as an opportunity to develop a new therapy that could benefit from orphan drug status, offering potential market exclusivity and other incentives.
For further insights into TSE:CRDL stock, check out TipRanks’ Stock Analysis page.
